ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. ZNTL is trading in a weak short-term downtrend with bearish momentum (negative and expanding MACD histogram) and has slipped below a key support zone (S1 ~2.447), suggesting downside risk toward ~2.22 before a cleaner bounce setup appears. With no Intellectia signals today and fundamentals still loss-heavy, an impatient buyer is better off not entering at this level.
Price action is weak: the stock closed around 2.38 and is below the pivot (2.813) and below first support (S1 2.447), a technically bearish breakdown that often invites continuation selling. MACD histogram (-0.116) is below zero and negatively expanding, confirming bearish momentum. RSI(6) ~33 is near oversold but not clearly signaling a reversal yet. Key levels: downside support at S2 ~2.22; reclaiming 2.45 (S1) would be the first sign of stabilization; stronger confirmation would be a move back above the pivot 2.813, with resistance at 3.18 then 3.407.
Insider activity is a meaningful positive: insiders are reported as buying, with a sharp increase in buying activity over the last month. Pipeline progress noted by analysts: enrollment ongoing in the DENALI Part 2a study for azenosertib in platinum resistant ovarian cancer. Call-heavy options open interest can also reflect some speculative bullish positioning.
with negative MACD momentum. No fresh news catalysts in the past week to reverse sentiment. Fundamental profile remains weak (no meaningful revenue; losses widening). Analyst sentiment has deteriorated via a significant price target cut, reflecting lowered peak sales expectations and reduced revenue assumptions for non-gynecological indications. Hedge funds are described as neutral (no supportive positioning trend).
Latest reported quarter: 2025/Q3. Revenue remains effectively zero (no growth), while profitability deteriorated: net income fell to about -$26.7M (worse YoY), and EPS declined to -0.37 (worse YoY). Gross margin dropped to 0 (down sharply). Overall, the quarter shows continued cash-burn/loss profile without offsetting revenue momentum—unfavorable for near-term confidence.
Recent analyst action (2025-11-11): Morgan Stanley kept an Equal Weight rating but cut the price target to $4 from $8, driven by refined azenosertib revenue assumptions (increased PROC estimate, removed non-gynecological revenues, reduced peak sales estimate to ~$511M from ~$867M). Wall Street pro view: progress in the lead program and clinical enrollment supports optionality. Con view: commercial expectations were reset lower and the company is still loss-making with high clinical/regulatory execution risk and limited near-term financial leverage.
